Topic:

R&D

Latest Headlines

Latest Headlines

Kite taps Adimab to lend a hand in CAR-T R&D

Kite Pharma, at work on therapies that use the immune system to fight cancer, paired up with Adimab to expand its R&D efforts.

Bayer bets on Johns Hopkins for eye disease R&D

German pharma giant Bayer is uniting with researchers at Johns Hopkins University to ferret out new treatments for retinal diseases, signing a 5-year deal targeting early-stage R&D.

Israel's RedHill soars as its antibiotic comes through in Phase III

RedHill Biopharma's combo antibiotic for Helicobacter pylori infection met its main goal in a late-stage trial, putting the Israeli outfit in line for a sit-down with the FDA to plot a path to market.

Avalon, GlaxoSmithKline launch 3 new biotechs with $30M commitment

San Diego-based Avalon Ventures has doubled up on its pipeline of programs being developed in partnership with GlaxoSmithKline. The venture group has launched three new companies, plucking new drug projects that range from cardiovascular disease, to cancer to a rare lysosomal storage disorder.

Bluebird bio builds its case for gene therapy as first sickle cell patient responds

Bluebird bio took another step forward today in its carefully planned march toward a possible accelerated approval for its lead program, noting that their first sickle cell disease patient has been responding remarkably well to their therapy while adding evidence of improved durability in responses for beta-thalassemia.

GlaxoSmithKline's new asthma drug gets a split vote from FDA advisers

A group of FDA advisers backed GlaxoSmithKline's latest asthma treatment for use in adults but balked at recommending it for adolescents, setting the stage for a likely approval in the fall.

Agios' top cancer drug notches more remissions on the way to Phase III

Agios Pharmaceuticals' lead cancer drug extended its streak of promising clinical results, racking up remissions in an expanded Phase I trial as the company prepares for late-stage testing.

Oncology biotech BioAtla banks $30M from Chinese syndicate

San Diego's BioAtla has raised $30 million in equity from undisclosed Chinese investors, cash that will help push its pipeline of large-molecule treatments.

Unum hits the gas on next-gen CAR-T tech after banking $65M round

Hot on the heels of executing a $645 million deal to work with Seattle Genetics on a portfolio of antibody-coupled T-cell receptor programs, Cambridge, MA-based Unum Therapeutics has taken the wraps off a whopping $65 million crossover round aimed at fueling their drive into the clinic with their next-gen approach to CAR-T.

J&J's global hunt for new drugs, cool new tech spurs 17 new deals

Johnson & Johnson today took the wraps off its latest collection of collaborations aimed at everything from setting up new "asset-centric" drug development operations with a partner in China to exploring ways to prevent Type 1 diabetes with investigators at Washington University. Its latest tally of 17 new deals and developments also includes a new Innovation hub in Sweden and brings its global total for its deal teams to more than 200 projects over two years running.